生物疗法对气道过敏反应和过敏反应的影响:系统文献综述
Joseph D Spahn1, Christopher E Brightling2, Paul M O'Byrne3
1Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA.
Journal of asthma and allergy
|July 27, 2023
概括
像奥马利祖马布和特泽佩卢马布这样的生物疗法可以减少喘息患者的呼吸道过敏反应 (AHR) 和过敏反应. 德泽佩卢马布对过敏原特异性和非过敏性AHR均表现出广泛的有效性.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 气道过敏反应 (AHR) 是喘的一个标志.
- 生物疗法针对喘中的特定炎症途径.
- 了解生物对AHR的影响揭示了疾病病理生理学.
研究的目的:
- 审查关于对喘中过敏原特异性和非过敏原特异性呼吸道反应的生物学影响的证据.
- 阐明各种生物制剂对AHR,早期过敏反应 (EAR) 和晚期过敏反应 (LAR) 的影响.
主要方法:
- 按照PRISMA指南进行系统审查.
- 在PubMed和Ovid搜索随机,安慰剂对照试验 (1997-2021).
- 包括评估生物药物对喘患者的AHR,EAR和/或LAR影响的研究.
主要成果:
- 在一些研究中,奥马利祖马布减少了AHR,EAR和LAR.
- 德泽佩卢马布可以减少AHR,EAR和LAR.
- 梅波利祖马布,乙坦塞普特和皮特拉金拉对AHR,EAR或LAR的影响有限或不存在.
- 其他几种生物药物对AHR,EAR或LAR没有显著影响.
结论:
- 奥马利祖马布和特泽佩卢马布有效降低过敏反应 (EAR和LAR).
- 德泽佩卢马布显示,对各种刺激来说,AHR的持续降低.
- 德泽佩卢马布似乎广泛针对过敏和非过敏的AHR,为喘机制提供了洞察力.
更多相关视频
相关概念视频
Drugs Used in Lower Respiratory Disorders: Overview
490
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
490
Antiasthma Drugs: β2-Adrenoceptor Agonists
308
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
308
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
348
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
348
Asthma: Pathogenesis and Management
447
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
447
Antiasthma Drugs: Leukotriene Modifiers
365
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
365
Allergic Drug Reactions
879
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
879


